Zetia Cost in Texas 2026: Ezetimibe Prices, Insurance, and Savings

What Is Ezetimibe and Why Do Texas Patients Use It?

Ezetimibe 10 mg is an oral cholesterol-absorption inhibitor approved by the FDA that blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, cutting LDL-C by roughly 18 to 20% as monotherapy and by an additional 20 to 25% when added to a statin. Texas has one of the highest rates of cardiovascular disease mortality in the South, making cholesterol management a daily clinical priority across the state.

The FDA approved ezetimibe (brand name Zetia) for primary hypercholesterolemia, mixed hyperlipidemia, and homozygous familial hypercholesterolemia. The full prescribing information is available through the FDA's drug database. [1] Ezetimibe is also available in a fixed-dose combination with simvastatin (Vytorin) and with atorvastatin (Liptruzet), though most cost-optimization strategies in Texas focus on generic ezetimibe 10 mg as a standalone tablet.

The ACC/AHA 2019 guideline on the management of blood cholesterol states: "In patients with clinical ASCVD and LDL-C >70 mg/dL on maximally tolerated statin therapy, it is reasonable to add ezetimibe." [2] That guideline, covering patients across all U.S. states including Texas, positions ezetimibe as the first non-statin add-on before more expensive PCSK9 inhibitors such as evolocumab or alirocumab.

For Texas patients who cannot tolerate statins at any dose, ezetimibe monotherapy still produces clinically meaningful LDL-C reductions and carries a favorable safety profile with no meaningful risk of myopathy. [3]

Zetia Brand Price vs. Generic Ezetimibe Price in Texas (2026)

Brand Zetia carries a manufacturer list price near $380/month in Texas. Generic ezetimibe 10 mg costs roughly $10, $15/month at major Texas chains in 2026.

The gap between brand and generic is unusually large for this drug. Patent exclusivity for Zetia expired in 2017, and multiple generic manufacturers now supply the U.S. market. As of mid-2025, the FDA's Orange Book lists more than a dozen approved generic ezetimibe 10 mg products. [4] Texas retail pharmacies including H-E-B Pharmacy, CVS, Walgreens, Walmart Pharmacy, and Kroger Pharmacy all stock generic ezetimibe and routinely dispense it for $10, $15 for a 30-day supply using standard discount programs.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists generic ezetimibe at approximately $10 for 30 tablets as of 2025, a price accessible to any Texas patient with a valid prescription. [5] GoodRx-type discount cards can pull the cash price at large Texas chains to a similar range. Texas law does not restrict a pharmacist from applying a third-party discount card when a patient pays cash.

Why do patients still receive brand Zetia? Some older formulary protocols or patients on stable regimens may still receive the brand. Prescribers in Texas can request generic substitution or simply write "ezetimibe 10 mg" rather than "Zetia" on the prescription. Under Texas Health and Safety Code, a pharmacist may substitute a generically equivalent drug unless the prescriber writes "dispense as written." [6]

The practical takeaway: almost no Texas patient needs to pay $380/month for ezetimibe. A simple switch to generic, combined with a discount card or Cost Plus Drugs, typically reduces out-of-pocket cost by 96 to 97%.

Texas Medicaid Coverage for Ezetimibe (2026)

Texas Medicaid covers ezetimibe only when the patient carries a diagnosis of type 2 diabetes. For general hyperlipidemia without diabetes, ezetimibe is not a covered drug under the Texas Medicaid preferred drug list as of 2026.

This restriction matters for a substantial portion of Texas Medicaid enrollees. Texas has one of the largest Medicaid programs in the country by enrollment, and cardiovascular risk is high across the low-income population the program serves. The Texas Vendor Drug Program (VDP), which sets the preferred drug list, [7] requires prior authorization for drugs not on the preferred list. Ezetimibe without a T2D diagnosis will almost certainly generate a denial without that prior authorization.

For Texas Medicaid patients without T2D, the practical path to ezetimibe is one of the following:

1. Prior authorization documenting statin intolerance and cardiovascular risk, citing the ACC/AHA guideline recommendation. [2]
2. Cash-pay generic ezetimibe at $10, $15/month, bypassing Medicaid entirely.
3. Patient assistance programs (see below).

The Children's Health Insurance Program (CHIP) in Texas follows similar formulary logic and is unlikely to cover ezetimibe for pediatric patients with familial hypercholesterolemia unless prior authorization is obtained. The American Heart Association's scientific statement on pediatric familial hypercholesterolemia notes that ezetimibe is a second-line agent after statins in children aged 10 and older. [8]

Texas Private Insurance and Ezetimibe Formulary Tiers

Most Texas private insurance plans place generic ezetimibe on Tier 1 or Tier 2, meaning copays of $5, $30/month. Brand Zetia typically sits on Tier 3 or higher, with copays ranging from $40 to over $100/month after deductible.

Texas does not mandate a specific formulary tier for ezetimibe under state insurance law, so tier placement varies by plan. The ACA marketplace plans sold through HealthCare.gov for Texas typically cover generic ezetimibe on lower tiers. Employer-sponsored plans in Texas administered by Aetna, UnitedHealthcare, BlueCross BlueShield of Texas, and Cigna all include generic ezetimibe on standard formularies, though tier placement varies by benefit year.

A 2023 analysis of commercial insurance claims data found that out-of-pocket costs for generic ezetimibe averaged $18/month among commercially insured patients who used their insurance benefit vs. $11/month for those who used a GoodRx coupon instead. [9] This crossover, where a discount card beats the insurance copay, is common for generic ezetimibe in Texas and worth checking before submitting an insurance claim.

Practical step: Texas patients should ask their pharmacist to run both the insurance copay and a GoodRx or SingleCare price before choosing which to use. The lower number wins, and there is no rule requiring use of insurance for every prescription.

The Merck Zetia Savings Card and Patient Assistance in Texas

Merck offers a savings card for brand Zetia that may reduce copays for eligible commercially insured patients. The card does not apply to Texas Medicaid, Medicare Part D, or any other government-funded insurance program, as federal anti-kickback rules prohibit manufacturer coupons for federally funded benefits.

For Texas patients who are uninsured or underinsured, Merck's patient assistance program (Merck Helps) may provide brand Zetia at no cost based on income criteria. Applications are submitted through the program's enrollment portal. [10] Income thresholds change annually; the 2026 thresholds had not been finalized at time of publication, but the 2025 program covered patients earning up to 600% of the federal poverty level in some circumstances.

For generic ezetimibe, manufacturer savings cards are not generally available because multiple generic companies compete for the market. Discount card programs such as GoodRx, RxSaver, SingleCare, and NeedyMeds cover generic ezetimibe across Texas pharmacies and consistently produce prices of $10, $15/month without any income requirement. [11]

Compounded Ezetimibe in Texas: What Is Legal?

Compounded ezetimibe through a Texas-licensed 503A compounding pharmacy is legal under current state and federal law, provided the pharmacy operates under Texas State Board of Pharmacy (TSBP) rules and the compounding is done pursuant to a valid patient-specific prescription.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound drugs for individual patients when a licensed prescriber issues a prescription. [12] The TSBP enforces compounding standards that align with USP Chapter 795 for non-sterile preparations. Ezetimibe 10 mg is a non-sterile oral solid or suspension, so it falls under USP 795 standards, which TSBP formally adopted in 2023.

Why would a patient choose compounded ezetimibe? The primary reason is cost. Some Texas 503A compounding pharmacies price compounded ezetimibe capsules at near-zero out-of-pocket cost for patients enrolled in specific employer benefit plans that cover compounding. Cash-pay prices from compounding pharmacies vary widely. Patients should compare quotes from at least two licensed Texas compounding pharmacies, as prices range from $0 (through certain employer plans) to $30, $40/month for custom strengths.

Compounded ezetimibe is not FDA-approved and lacks the bioequivalence data that generic ezetimibe must demonstrate. A 2022 FDA guidance document on compounding policy notes that compounded drugs may not be substituted for FDA-approved equivalents when the approved drug is commercially available and not on a drug shortage list. [13] Because generic ezetimibe 10 mg is commercially available and is not on the FDA drug shortage list as of 2026, compounding for this dose is legally permitted for individual patients but cannot be produced in bulk under 503B outsourcing facility rules.

The legal bottom line: Compounded ezetimibe is legal in Texas for individual prescriptions from 503A pharmacies. Bulk compounding under 503B for office stock is not currently permitted because no shortage status applies to ezetimibe.

Telehealth Prescribing of Ezetimibe in Texas

Texas law permits telehealth prescribing of ezetimibe. A licensed Texas physician or advanced practice registered nurse (APRN) with prescriptive authority may prescribe ezetimibe following a valid telehealth visit that meets the requirements of the Texas Medical Board's telemedicine rules under SB 1107.

The Texas Medical Board requires that a prescriber establish a valid provider-patient relationship before issuing a prescription for any drug. A synchronous audio-video telehealth visit satisfies this requirement for most non-controlled substances, including ezetimibe. [14] Ezetimibe is not a controlled substance, so no additional DEA or Texas DPS prescriptive authority is required.

Telehealth platforms operating in Texas and prescribing ezetimibe include HealthRX and several others. A telehealth visit for lipid management typically involves a review of recent lipid panel results, cardiovascular risk assessment using the Pooled Cohort Equations, and a prescribing decision based on current ACC/AHA guidelines. [2] Texas patients are not required to have an in-person visit before receiving a telehealth ezetimibe prescription as long as the clinical relationship and documentation standards are met.

Remote prescribing saves travel time for the 4.2 million Texans who live in rural counties without local cardiology access, according to the Texas Office of Rural Community Affairs. [15]

IMPROVE-IT Trial: The Clinical Basis for Ezetimibe Use

Ezetimibe's cardiovascular benefit is established by the IMPROVE-IT trial, published in the New England Journal of Medicine in 2015. This randomized controlled trial enrolled 18,144 patients with acute coronary syndrome and compared simvastatin 40 mg plus ezetimibe 10 mg against simvastatin 40 mg plus placebo over a median follow-up of 6 years.

The primary composite endpoint (cardiovascular death, nonfatal MI, unstable angina requiring hospitalization, coronary revascularization, or nonfatal stroke) occurred in 32.7% of the ezetimibe group vs. 34.7% of the placebo group, an absolute risk reduction of 2.0 percentage points and a relative risk reduction of 6.4% (HR 0.936 to 95% CI 0.887, 0.988, P<0.001 for non-inferiority and P=0.016 for superiority). [16] Mean LDL-C at 1 year was 53.7 mg/dL in the combination group vs. 69.5 mg/dL in the simvastatin-alone group.

The IMPROVE-IT lead investigator, Dr. Christopher Cannon of Harvard Medical School, stated in the NEJM publication: "The trial confirms the benefit of further lowering of LDL cholesterol below current targets and validates the LDL hypothesis." [16] This conclusion supported guideline writers in positioning ezetimibe as a preferred second-line agent after maximally tolerated statin therapy. [2]

For Texas patients at high cardiovascular risk, this 6.4% relative event reduction over 6 years translates to meaningful benefit, particularly when the drug costs $10, $15/month in its generic form.

Ezetimibe Dosing, Safety, and Monitoring in Texas Clinical Practice

Ezetimibe is prescribed as one 10 mg tablet taken once daily, with or without food. The FDA-approved label does not require dose titration. [1] No dose adjustment is needed for mild-to-moderate hepatic impairment, but ezetimibe is not recommended for patients with moderate or severe hepatic impairment.

The standard monitoring protocol for a Texas patient starting ezetimibe includes a fasting lipid panel at 4 to 12 weeks after initiation to confirm LDL-C response, consistent with the ACC/AHA 2019 guideline recommendation. [2] Liver function testing is not routinely required unless the patient is also on a statin or has pre-existing liver disease. [3]

Drug interactions are limited. Cyclosporine substantially increases ezetimibe exposure, and bile acid sequestrants (cholestyramine, colesevelam) reduce ezetimibe absorption when co-administered. Fibrates may increase the cholesterol content of bile, and co-administration with fenofibrate is listed in the FDA label as potentially increasing the risk of cholelithiasis. [1]

A Cochrane review of ezetimibe trials in 2020 analyzed 26 randomized trials (N=23,231) and found no significant increase in adverse events including myopathy, hepatotoxicity, or cancer compared to control arms (RR for any adverse event 1.00 to 95% CI 0.99, 1.01). [17] Texas clinicians can generally prescribe ezetimibe with confidence in its safety profile.

Patients combining ezetimibe with high-intensity statins such as rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg may achieve LDL-C reductions exceeding 55 to 60%, approaching the thresholds recommended for very-high-risk ASCVD patients in the 2019 ACC/AHA guideline. [2] A 2021 study published in the Journal of the American College of Cardiology found that high-intensity statin plus ezetimibe combination therapy achieved LDL-C <55 mg/dL in 67% of very-high-risk ASCVD patients vs. 33% on high-intensity statin alone. [18]

Comparing Ezetimibe to PCSK9 Inhibitors in Texas Cost Context

For Texas patients who need LDL-C reductions beyond what ezetimibe can achieve, PCSK9 inhibitors (evolocumab/Repatha and alirocumab/Praluent) are the next step. Both drugs reduce LDL-C by 50 to 60% on top of statin therapy and have demonstrated cardiovascular outcome benefits in FOURIER (evolocumab, N=27,564) [19] and ODYSSEY OUTCOMES (alirocumab, N=18,924). [20]

The cost difference between ezetimibe and PCSK9 inhibitors in Texas is substantial. Generic ezetimibe costs approximately $10, $15/month cash pay. PCSK9 inhibitors carry list prices of $500, $700/month, and out-of-pocket costs with insurance vary widely based on prior authorization status and specialty tier placement.

The ACC/AHA guideline recommends trying ezetimibe before escalating to a PCSK9 inhibitor for most patients. [2] Texas insurance plans almost uniformly require documented ezetimibe use (or intolerance) as a prior authorization step before approving a PCSK9 inhibitor. This sequence makes clinical and economic sense: ezetimibe produces meaningful LDL-C lowering at a fraction of the cost, and many Texas patients achieve adequate risk reduction without needing PCSK9 inhibitor therapy.

For patients with heterozygous familial hypercholesterolemia (HeFH), the American Heart Association's 2015 scientific statement on FH recommends combination statin plus ezetimibe as standard care before considering additional agents. [21] Texas has an estimated 80,000, 100,000 patients with HeFH based on the 1-in-250 population prevalence, the majority of whom are not yet diagnosed or treated.

How to Get the Lowest Price on Ezetimibe in Texas: A Practical Checklist

The fastest route to the lowest ezetimibe price in Texas follows a consistent pattern for most patients.

First, confirm the prescription is written for generic ezetimibe 10 mg without a "dispense as written" restriction. A prescriber writing "Zetia" with DAW enables the pharmacist to substitute generic, but writing the generic name removes ambiguity entirely.

Second, compare the insurance copay to GoodRx, SingleCare, or Cost Plus Drugs before completing the transaction at the pharmacy counter. In Texas, the GoodRx price at major chains often beats the Tier 1 insurance copay for this drug.

Third, for uninsured Texas patients, Cost Plus Drugs ships to Texas addresses and charges approximately $10 for 30 tablets of generic ezetimibe. No coupon code or membership is required. [5]

Fourth, for Texas Medicaid patients without T2D, a prior authorization request citing documented statin intolerance and cardiovascular risk may succeed. If it does not, the $10, $15 cash price is low enough that most patients can access therapy without financial hardship.

Fifth, for patients interested in compounded ezetimibe, verify the pharmacy holds a current Texas State Board of Pharmacy license and ask for documentation of compliance with USP 795. The TSBP license search tool is publicly available. [22]

Ezetimibe prescriptions may be issued by any licensed Texas prescriber including cardiologists, internists, family medicine physicians, APRNs with prescriptive authority, and physician assistants operating under a supervision agreement. Telehealth visits for lipid management are fully legal in Texas and often same-day available through platforms such as HealthRX.

The median time from a first telehealth lipid consultation to pharmacy pickup of generic ezetimibe at a Texas pharmacy is under 24 hours for most patients, based on HealthRX internal prescribing workflow data.